Document Type
Rapid Review
Review Code
EOC072102 RR
Question Submitted
July 27, 2020
Date Completed
July 31, 2020
Status
3. Completed
Research Team
EOC
Document Type
Rapid Review
Review Code
EOC072102 RR
Question Submitted
July 27, 2020
Date Completed
July 31, 2020
Status
3. Completed
Research Team
EOC
Key Findings
· Children and adolescents (0 to 18 years) contributed 1- 10% of laboratory confirmed cases of COVID-19 globally. · Children have been reported to have milder symptoms of COVID-19 and have shown better prognosis as compared to adults. · Severe cases presenting as a multisystem inflammatory syndrome in children (MIS-C) has been reported in some pediatric cases of COVID-19. Many of these children meet the criteria for complete or incomplete Kawasaki disease, but different clinical presentations of this inflammatory disorder are being reported. · Underlying medical conditions and comorbidities such as such as sickle cell disease, immunocompromised condition, obesity, cancer, cardiovascular disease, and asthma have been associated with severity and complications from COVID-19 infection in pediatric patients. · Although rare, death from COVID-19 in children have been reported, with a case fatality rate of less than 0.5%.
Category
Epidemiology
Subject
Pediatrics
Natural History
Symptoms
Transmission
Population
All Pediatrics
Priority Level
Level 5 completed within 2 weeks
Cite As
Asamoah, G; Muhajarine, N; Dalidowicz, M; Ellsworth, C; Howell-Spooner, B. What is the disease progression and epidemiology of COVID-19 in pediatric populations? 2020 Jul 27; Document no.: EOC072102 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 17 p. (CEST rapid review report)
Related Documents
Documents
Less detail